1、 Institute for Clinical and Economic Review,2026 B-Cell Directed Therapies for IgA Nephropathy:Effectiveness and Value Evidence Report FEBRUARY 9,2026 Prepared for Institute for Clinical and Economic Review,2026 Page i Evidence Report:B-Cell Directed Therapies for IgA Nephropathy ICERs value assessm

2、ents are free from financial conflicts of interest from health care companies.As an organization,we value transparency and hold ourselves,and our collaborators,to high standards for conducting our work.Our full policy to manage potential conflicts of interest can be found here.You can find ICERs Cod

3、e of Ethics here.Any conflicts reported by the authors of this report,contributing staff members,or expert reviewers can be found on page v.DATE OF PUBLICATION:February 9,2026 How to cite this document:Wasfy JH,McQueen RB,McKenna A,Distefano MJ,Lee W,Zemplenyi A,Phillips M,Paratane D,Rind DM.B-Cell

4、Directed Therapies for IgA Nephropathy:Effectiveness and Value;Evidence Report.Institute for Clinical and Economic Review,February 9,2026.https:/icer.org/wp-content/uploads/2026/02/ICER_IgAN_Evidence-Report_For-Publication_020926.pdf ICER Staff and Consultants The University of Colorado Modeling Tea

5、m Jason H.Wasfy,MD,MPhil Associate Professor at Harvard Medical School,Director of Outcomes Research,Massachusetts General Hospital Cardiology Division Mass General Brigham Avery McKenna,BS Research Lead Institute for Clinical and Economic Review Woojung Lee,PharmD,PhD Associate Director of Health E

6、conomics and Decision Modeling Institute for Clinical and Economic Review Marie Phillips,BA Health Economics Research Assistant Institute for Clinical and Economic Review David M.Rind,MD,MSc Chief Medical Officer Institute for Clinical and Economic Review R.Brett McQueen,PhD Associate Professor Skag